Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia BRITISH JOURNAL OF HAEMATOLOGY Advani, A. S., Gundacker, H. M., Sala-Torra, O., Radich, J. P., Lai, R., Slovak, M. L., Lancet, J. E., Coutre, S. E., Stuart, R. K., Mims, M. P., Stiff, P. J., Appelbaum, F. R. 2010; 151 (5): 430-434


Clofarabine and cytarabine target different steps in DNA synthesis and replication, are synergistic in vivo, and have non-overlapping toxicities, making this combination a potentially promising treatment for acute lymphocytic leukaemia. Thirty-seven patients were treated. The median age was 41 years, 44% of patients were either in =2nd relapse or had refractory disease and 59% of patients had poor risk cytogenetics. Six out of 36 patients (17%) achieved a complete remission with or without complete count recovery; median overall survival was 3 months. Nucleoside transporter expression did not predict outcome. This regimen lacked sufficient activity to warrant further testing.

View details for DOI 10.1111/j.1365-2141.2010.08387.x

View details for Web of Science ID 000284169700003

View details for PubMedID 21113977